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Abstract
Purpose of review The remarkable advances in modern med-
icine have paradoxically resulted in a rapidly expanding pop-
ulation of immunocompromised patients displaying extreme
susceptibility to life-threatening fungal infections. There are
currently no licensed vaccines, and the prophylaxis and ther-
apy of fungal infections in at-risk individuals remains chal-
lenging, contributing to undesirable mortality and morbidity
rates. The design of successful antifungal preventive ap-
proaches has been hampered by an insufficient understanding
of the dynamics of the host-fungus interaction and the mech-
anisms that underlie heterogenous immune responses to vac-
cines and immunotherapy.
Recent findings Recent advances in proteomics and
glycomics have contributed to the identification of candidate
antigens for use in subunit vaccines, novel adjuvants, and
delivery systems to boost the efficacy of protective
vaccination responses that are becoming available, and several
targets are being exploited in immunotherapeutic approaches.
Summary We review some of the emerging concepts as well
as the inherent challenges to the development of fungal vac-
cines and immunotherapies to protect at-risk individuals.
Keywords Fungal disease . Vaccination . Aspergillus .
Candida . Immunotherapy . Personalizedmedicine
Introduction
In the last decades, the number of immunocompromised patients
has increased, mostly due to advances inmedical care, long-term
hospitalization, and prophylactic treatments in patients at-risk, as
well as due to acquired (e.g., HIVinfection) or treatment-induced
immunodeficiency in patients receiving hematopoietic stem-cell
or solid organ transplants, or undergoing anticancer therapy
[1–3]. Because of the complex underlying immune dysfunction,
these patients are not able to efficiently eliminate opportunistic
and otherwise commensal fungi, and are extremely susceptible
to severe infections, ranging from superficial mucocutaneous
disease to invasive deep-seated infections [4].
Currently available antifungal drugs have been proved ef-
ficient in in vitro and animal models of fungal disease; how-
ever, intrinsic activity against specific fungi is often lacking,
and for those with anti-mold activity, resistance has become a
worldwide concern [5•]. In addition, there are significant lim-
itations in the sensitivity of diagnostic tests, which can delay
the administration of proper antifungal therapy and lead to
fatal outcomes [6]. While the troublesome mortality and mor-
bidity rates have prompted efforts towards the development of
new drugs and diagnostics, they have also encouraged re-
search into vaccines to protect patients at-risk and to treat
those with overt disease. Here, we review some of the
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emerging concepts in fungal vaccine and immunotherapy de-
velopment, provide examples of promising approaches, and
define the main challenges in delivering them to specific target
populations.
Activation of Antifungal Immunity
The skin and the mucosal epithelial surfaces at body sites
constantly exposed to environmental microorganisms provide
the first line of innate resistance against fungal infection [7].
Epithelial cells are pivotal in discriminating commensal and
pathogenic fungal morphotypes and act as an active extension
of the innate immune system, operating as a surveillance
mechanism sensing fungi and prompting antifungal effector
responses [8, 9]. Innate immune cells, including macrophages
and dendritic cells (DCs), express a vast repertoire of pattern
recognition receptors (PRRs) able to sense pathogen-
associated molecular patterns and activate effector programs
such as phagocytosis and production of oxygen radicals
[10••]. In addition, specific molecules from the innate immune
system such as collectins, ficolins, pentraxins, and comple-
ment components play a critical role in assisting fungal sens-
ing by acting as opsonins and facilitating the interaction of
phagocytes with fungi [11].
The activation of different profiles of adaptive immunity
with both protective and non-protective functions against fun-
gal pathogens is only possible due to the multiple sensing
mechanisms existing in the innate arm of antifungal immunity
(Fig. 1). Antigen-presenting cells such as DCs are responsible
for sampling antigenic material in the environment and prim-
ing T cells via presentation of antigens on major histocompat-
ibility complex class II or class I molecules, leading to the
differentiation of CD4+ or CD8+ T cells, respectively [12].
Based on the expression pattern of lineage-specific transcrip-
tion factors and production of cytokines after priming of naïve
CD4+ T cells, the response is typically defined as T helper
(Th)1, Th2, Th17, or T regulatory (Treg). Priming of naïve
CD8+ T cells instead leads to differentiation of cytotoxic T
(Tc) cells. The key ability of DCs to decode fungal antigens
and translate them into qualitatively assorted adaptive T cell
immune responses positions them as logical cellular targets
for the development of fungal vaccination strategies [13, 14].
Generation of diverse T cell immune responses is a crucial
hallmark of adaptive antifungal immunity. Specifically, Th1
responses driven by IL-12 are required for the expression of
protective immunity to fungi and are regarded as central for
the design of effective fungal vaccines [15]. Induction of Th1
cells is required for the optimal activation of phagocytes at
sites of infection, through the release of interferon (IFN)-γ
and by supporting the production of opsonizing antibodies.
Th1 cell-based cross-protection has been accomplished with
a universal immunogenic epitope from the cell wall of
Aspergillus fumigatus [16]. Because these protective Th1 cells
cross-react with different fungi, and can be rapidly and effi-
ciently immunoselected, the exciting possibility of adoptive
fungus-specific T cell transfer for prophylaxis or treatment of
patients at-risk is proposed [17•]. Another step forward to-
wards a pan-fungal vaccine was recently provided by the iden-
tification of a widely conserved CD4+ T cell fungal epitope
that binds a peptide derived from fungal calnexin [18•].
Calnexin, primarily known for its chaperone function in mam-
malian cells, is displayed on the cell surface of many fungi,
and its inclusion in vaccine formulations was shown to induce
resistance against multiple fungal pathogens, remarkably
Blastomyces dermatitidis and Coccidioides posadasii, in mu-
rine models of vaccine immunity. It is also noteworthy that
human pathogen- and vaccine-specific Th1, Th17, and Th2
memory cells display different frequencies but comparable
diversity, and comprise not only clones polarized towards a
single fate but also clones whose progeny has acquired mul-
tiple fates [19]. These findings unravel an unexpected degree
of interclonal and intraclonal functional heterogeneity of the
human T cell response and suggest that polarized responses
resulting from the preferential expansion rather than priming
are a factor to be considered in vaccine design.
In addition to Th1, Th17 cells play a key role in antifungal
immunity, a concept supported by several clinical studies
reporting Mendelian susceptibility to fungal infections of in-
dividuals with inborn errors of dectin-1, caspase recruitment
domain-containing protein 9 (CARD9), signal transducer and
activator of transcription (STAT)1, STAT3, and specifically,
IL-17 immunity [20–23]. In experimental fungal infections,
however, IL-17-dependent immunity has been reported to dis-
play both essential and dispensable roles [24], a finding
pointing to a critical requirement of this pathway on specific
stages and sites of infection, and to depend on the pathogen
involved. In addition, Th17 cells are present in the fungus-
specific T cell memory repertoire in humans [25, 26] and
arbitrate some [27], but not all [28] vaccine-induced protec-
tion in mice, a finding highlighting an important regulatory
function of the Th17 pathway on multiple adaptive immunity
pathways. Different fungal morphotypes were recently found
to induce distinct adaptive immune responses, with Th17 cell
responses providing protection against cutaneous infection,
while Th1 cell responses provided protection against systemic
infection [29]. Altogether, these findings provide novel in-
sights into the compartmentalization of antifungal Th cell re-
sponses and have critical implications for vaccine develop-
ment strategies.
Challenges and Opportunities in Fungal Vaccination
Despite several efforts in the last years to produce a safe and
effective vaccine against fungal disease, no significant
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progress has been witnessed [30]. Because of the burden
posed by fungal infections on worldwide healthcare systems,
clinicians, researchers, and representatives of the pharmaceu-
tical industry have strengthened their efforts on the develop-
ment of antifungal vaccines. In recent years, several vaccine
candidates have been reported, refined, and tested in animal
models for their safety, immunogenicity, and efficacy, and at
least two of them are now under study in human clinical trials
[31]. A list with the major fungal vaccine candidates is shown
in Table 1.
There are clinical settings in which the need for antifungal
vaccines is more pronounced, namely those consisting of im-
munocompromised or debilitated hosts. Individuals with he-
matological malignancies and cancer, and that need to be sub-
jected to transplant and/or immunosuppressive anticancer
therapy immediately after diagnosis are highly susceptible to
develop aggressive fungal infections such as invasive asper-
gillosis or deep-seated candidiasis. Unfortunately, there are
some considerable obstacles that delay the implementation
of vaccination strategies in these patients. Although claims
that residual effective immune responses could effectively
deal with the pathogen even after removal or loss of major
groups of cells with antifungal effector ability [52, 53], the
question remains as to whether a long-term protection could
be obtained in these subjects, taking into account their under-
lying immune defect. One potential solution to ensure that
molecular mechanisms involved in regulating vaccine-
related immune responses do not breakdown after immuniza-
tion would be the use of novel vaccine formulations contain-
ing potent adjuvants aimed at eliciting protective responses
[54].
Individuals with no obvious immune deficits, but that are
placed at risk of life-threatening as the result of specific med-
ical interventions, could benefit from these approaches. For
example, patients who are certain to be immunosuppressed in
the future, such as those in stem-cell transplant waiting lists,
could be vaccinated prior to treatment while their immune
response is intact [55•]. However, vaccine development for
this group poses a problem of leaving too narrow a window
before starting treatment to consider vaccination and/or initi-
ate an appropriate schedule of vaccination. Another group of
patients that could benefit from fungal vaccination include
patients with breaches in their cutaneous or mucosal defenses,
bearing permanent central venous catheters, or undergoing
long-term hospitalization in intensive care units. Because of
the possible side effects associated to the use of these ap-
proaches in this setting of patients, vaccine design should
consider the nature of the relationship between opportunistic
fungi and their human hosts [56]. For example, vaccination
against commensals may disrupt the asymptomatic and possi-
bly beneficial relationship between the fungus and its host. In
the case of fungal pathogens with the ability to establish la-
tency or to cause chronic or recurrent infections, vaccination
may pose the risk of reactivating the target pathogen. Finally,
vaccination-related exacerbations of allergic responses may
arise when vaccinating against molds causing allergic disease.
In this case, a successful vaccine strategy could be to dampen
or redirect the nature of the immune response such as by
shifting the bias from Th2 to Th1 responses.
Another important challenge to vaccine development is the
testing of candidates in mice. While the human and murine
immune systems might be regarded as quite similar, most
Fig. 1 Cellular and humoral immunity to fungi. Shown are the different correlates of protection elicited either by B cells and secreted antibodies
(humoral immunity) or through the activity of T helper and cytotoxic T cells (cell-mediated immunity)
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studies have used inbred mice that lack the genetic diversity of
“outbred” humans. Perhaps more importantly, laboratorymice
do not have a natural exposure to certain airborne fungi (e.g.,
Aspergillus spp.), which contrasts with humans, who are re-
peatedly exposed to them during their lifetime. One possible
solution for this caveat would be the use of humanized mouse
models, modeling natural exposure conditions by continuous
challenge, and conducting in vitro human testing.
Decoding Antifungal Immunity into Vaccination
Approaches
Given the array of fungal motifs present at the cell surface, as
well as those that become available to immune sensing upon
digestion of the fungus by phagocytic cells, it is obvious that
vaccine-induced protection to attenuated strains occurs through
distinct innate immune receptors and downstream signaling
adapters. In fact, significant changes in the expression of innate
immune receptors during naïve-to-effector-to-memory transition
have been revealed as one major early molecular signature upon
vaccination [57]. The innate arm of the immune system is gen-
erally viewed as non-specific and unable to confer memory.
Recently however, it has become clear that the innate immune
response not only confers immunity, but can be trained prior to
exposure to deliver immunological memory [58], a paradigm
that was previously only attributed to the adaptive immune sys-
tem. Monocytes and macrophages are among the main cells of
the innate immune arm that can be trained using fungalβ-glucan
and dectin-1-mediated signaling via epigenetic reprogramming,
particularly through histone trimethylation at H3K4 [59]. These
epigenetic changes lead to cellular activation, enhanced cytokine
production, and a change in the metabolic state of the cell with a
shift from oxidative phosphorylation to aerobic glycolysis [59,
60, 61••]. By endorsing a prolonged enhanced functional state in
monocytes and macrophages after adequate priming, induction
of trained immunitymay be regarded as a promising new avenue
for the design of fungal vaccines [62].
Active Immunotherapy
Fungal vaccines can be synonym of active immunotherapies as
they promote immune responses with the goal of challenging
and attacking fungal pathogens based on one or more specific
antigens [63]. A growing number of approaches have been de-
veloped to identify proteins able to induce an antibody response
or that represent targets of T cell immunity in patients with
allergy or fungal infection [64]. Most of the fungal vaccines
elicit antibody responses and their efficacy can be estimated
through titer thresholds which may serve as vaccine surrogate
markers even when the mechanism of protection is cell-
mediated [15]. Of note, the fungal vaccine under clinical trial
for vulvovaginal candidiasis relies on recombinant secreted
aspartic proteinase 2 proteins that induce protection through
elicitation of neutralizing antibodies at the vaginal mucosa [47].
Regarding activation of T cell responses, acquisition of vac-
cine immunity to live attenuated strains of several dimorphic
fungi was found to require induction of Th17 cells [27]. In
contrast, protection to A. fumigatus relied on the differentiation
of Th1 cells [28, 65]. Because these responses required different
innate sensing pathways to be activated, these findings point to a
crucial requirement of adjuvants in promoting T cell differenti-
ation along specific effector pathways [54]. In this regard, Th1-
mediated protection has been reported across nearly all clinically
relevant fungal diseases (Table 1). For example, among themost
important fungal vaccine candidates leading to induction of
Table 1 Major vaccine candidates against Aspergillus and Candida species
Target pathogen(s) Vaccine candidate(s) Antigen Mechanism(s) of protection Reference(s)
Aspergillus Asp f16, Asp f3, Pep1, Gel1, glucans Recombinant/subunit Th1 [26, 32, 33]
Aspergillus, Candida Crf1 Recombinant Th1 [16]
Aspergillus, Candida Heat-killed Saccharomyces cerevisiae Heat-killed whole Th1, Th2, Th17 [34, 35]
Aspergillus Particulate β-glucans Subunit Th1, Th17 [36]
Candida Als1, Als3, rAls3p-N (NDV-3)a Recombinant/subunit Th1, Th17, antibodies [37, 38]
Candida Fba peptide Subunit Antibodies [39, 40]
Candida Met6 peptide Subunit Antibodies [40]
Candida Hyr1 Recombinant/subunit Antibodies [41]
Candida Live attenuated Whole T cells, antibodies [42, 43]
Candida Mannan Recombinant/subunit Th1, antibodies [44, 45]
Candida Eno1 Recombinant Antibodies [46]
Candida Sap2p PEV-7a Recombinant truncated Antibodies [47]
Candida Laminarin Subunit Antibodies [48–50]
Candida Cell wall surface proteins Subunit Antibodies, Th17 [51]
a rAls3p-N (NDV-3) and Sap2p PEV-7 are under study in human clinical trials
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strong Th1 responses are crude antigen preparations from
A. fumigatus or recombinant fungal antigens alone [66–68] or
in conjunction with CpG oligonucleotides as adjuvants [16, 32,
69, 70] and the recombinant Als3p-N protein of Candida
albicans formulated with alum adjuvant (designated as NDV-3
and currently under clinical trial) [37]. On the other hand, fungi
have evolved their own complex mechanisms to subvert activa-
tion of effector T cell responses. For example, mucosal vaccina-
tion was found to prevent T cell priming by impairing chemo-
kine signals on egress of inflammatory monocytes from the
bone marrow and their recruitment to the lung [71]. Bearing in
mind that inflammatory monocytes are pivotal in orchestrating
pulmonary antifungal immunity by regulating neutrophil
conidiocidal activity and their own differentiation to DCs, the
fact that fungi can also modulate monocytes activity to prevent
T cell activation is even more significant in terms of vaccine
design [72].
The recent role proposed for metabolism [73••] and bioen-
ergetics [74] in harnessing Tcell memory and promoting rapid
recall rates opened up new perspectives on how epigenetic
and environmental mechanisms modulate memory differenti-
ation and quality, thus opening new avenues for vaccine de-
velopment. Additionally, subsets of T cells previously unan-
ticipated to be involved in immune memory may also become
important targets for new vaccines. One such example regards
the invariant natural killer T cells that activate antifungal re-
sponses and promote airway hyperreactivity through the rec-
ognition of β-glucan [75] and the glycosphingolipid
asperamide B [76]. Altogether, the currently available infor-
mation suggests that the development of a multivalent vaccine
inducing an immune response against multiple, unrelated fun-
gal virulence traits may be the best approach towards the first
antifungal vaccine approved for human use [31].
Passive Immunotherapy
Passive immunotherapy strategies comprise laboratory-
synthesized antibodies or other immune system components
that can be administered to patients and do not stimulate the
immune system nor “actively” respond to infection in the way a
vaccine does [77]. In this regard, a number of monoclonal
human recombinant antibodies and their fragments have al-
ready been tested in experimental fungal diseases [78].
Another example of passive immunotherapy regards the long
pentraxin 3 (PTX3), a soluble PRR which has been found to
play a pivotal role in the establishment of adequate protection
against invasive aspergillosis in allogeneic stem-cell transplant
recipients [79••]. Remarkably, PTX3 alone [80] or in combina-
tion with antifungals [81] was shown to confer protection in
animal models of invasive aspergillosis, therefore highlighting
the potential of this molecule as an immunotherapeutic target in
high-risk patients. In addition, the potential usefulness of PRR
agonists to treat fungal infections was also recently addressed
in a clinical trial assessing the efficacy of topical applications of
imiquimod (a Toll-like receptor 7 (TLR7) ligand) to treat pa-
tients afflicted with the chronic infection chromoblastomycosis
[82•].
Fungal Vaccination in the Era of Personalized
Medicine
The decoding of the complexity in the immune response to
vaccines demands for an integrative network comprising ad-
vanced immunology approaches, systems biology, and im-
munogenetics, in the areas of pathogen and host biology and
their interaction. Vaccinomics is a term that was recently
coined to describe the field of immunogenomics applied to
the elucidation of mechanisms accountable for interindivid-
ual immune responses to vaccines [83]. The genetic variabil-
ity of the immune system is nowadays recognized as one
major determinant of the quality of the antifungal immune
response, particularly in the relative absence of immune re-
dundancy observed in immunocompromised individuals [84,
85]. Therefore, genetic profiling of immune responses is
nowadays regarded as a promising approach to exploit in
the future towards improved diagnosis and therapy of fungal
diseases [86•]. More specifically, functional polymorphisms
in certain immune genes, including that coding for IFN-γ
[87], have been found to underlie variable immune re-
sponses to a given vaccine. Along the same line, the quali-
tative analysis of A. fumigatus-specific immune responses in
hematological patients has been proposed as a promising
immunodiagnostic approach [88•]. Thus, by interpreting im-
munogenetic signatures and identifying even subtle differ-
ences in immune profiles, it may be possible to discriminate
response efficiencies to antifungal vaccines. The finding that
the genetically determined deficiency of TLR3 compromises
the ability of DCs to activate protective memory CD8+ T
cells, thereby predisposing to invasive aspergillosis among
hematopoietic stem-cell transplant recipients, is one such
example [65].
Given the complexity of innate and adaptive antifungal
immune responses, data from functional genomics, tran-
scriptomics, proteomics, and metabolomics will probably be
required to provide the best performance in predicting vaccine
efficacy [89]. Within these examples, host microbiomics is of
particular interest due to their protective function against col-
onization by endogenous and exogenous microorganisms and
even in the modulation of host immune responses [90]. For
example, catabolites originating from the breakdown of tryp-
tophan by intestinal microbiota were found to activate the aryl
hydrocarbon receptor and fine-tune mucosal reactivity to
C. albicans [91], and dectin-1-mediated signaling was re-
quired to maintain intestinal immune homeostasis [92].
Whether the endogenous lung microbiota also plays a role in
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susceptibility to and progression of fungal diseases is current-
ly a hot topic of research [93]. Altogether, the comprehensive
information about the biology of the host-fungus interaction
and the intrinsic and extrinsic factors likely influencing the
development of disease could be used in the rational and per-
sonalized development of new vaccine candidates.
Concluding Remarks
Vaccination is unquestionably one of the major public health
successes in the history of medicine. However, since the first
safe and efficacious vaccine has eradicated smallpox, and after
more than a dozen lethal bacterial and viral infections have been
kept at bay by vaccination, effective fungal vaccines for clinical
use are not available. We have witnessed exciting recent devel-
opments in our understanding of the complex molecular and
cellular pathways through which the immune system controls
fungi and responds to infection. The combination of multidisci-
plinary approaches based on whole-genome and “omics” tech-
niques, advanced bioinformatics, and systems biology may fur-
ther contribute to the identification of novel immunogenic anti-
gens and cellular pathways amenable tomanipulation, as well as
novel adjuvants and delivery systems. Ultimately, this new con-
ceptual framework in vaccine discovery and design may lay the
foundation for the first successful fungal vaccines.
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